BIIB has been known to volatile at earning. This is a Biotch and warrants attention that we have run up nice and if they just report average earnings or no incredicble news then we could see good profit taking or more. If they miss ia it really worth the risk at these levels for the chance of a 15 point drop? Take profits here. Cheers, Coz.
With a p/e of 26, and 3-4 possible fda approvals in the next 12 months? Get real. This is one of the few with real drugs eating up market share with more to come. By the way, they don't need partners, though they may take one for future marketing.